Numerous epigenetic, HIF-targeted and miRNA-directed therapies have been examined in clinical trials [176–178], showing potential of targeting these kinds of molecules for cancer treatment, which might exert anti-tumor effects partly through altering ALKBH5-mediated m6A demethylation. The gene discussed is ALKBH5; the disease is neoplasm.